factor). This emphasizes the need to be aware of the different demands on the microcirculation, and the oftenconflicting drivers of an adaptive response. The pivotal role of VEGF in human health is reflected in attempts to inhibit activity as part of anticancer therapy, and enhance activity to overcome tissue ischaemia. Skeletal muscle offers a useful setting to explore in vivo regulation, as both mRNA expression and protein levels can be substantially elevated by heavy exercise. Interestingly, whereas global VEGF knockout is embryonic lethal, muscle-specific gene ablation is not, although VEGF − / − mice show decreased capillarity and fatigue resistance, whereas the angiogenic response to training is abolished. Underlying mechanisms are far from clear, but VEGF localizes to both vascular endothelium and skeletal muscle fibres, and myocyte VEGF may regulate muscle blood flow. This elegant approach generates apparently paradoxical results from interruption of upstream signalling: whereas HIF (hypoxia-inducible factor) is a key regulator of VEGF, and relative local hypoxia during exercise leads to elevated levels, both capillarity and performance are refractory to musclespecific HIF knockout. This helpful overview provided a timely reminder that, to fully understand biological activity of important molecules, we need to characterize the integrative response to physiological or pathological challenges. This in turn will lead to a better understanding of the fundamental mechanisms, and identify new therapeutic opportunities. Thomas Gustafsson [2] continues the VEGF/exercise story by examining the response profile in humans, showing that whereas VEGF mRNA expression is a transient event associated with individual bouts of exercise, steady-state VEGF protein levels increase throughout a training regime. Angiogenesis is clearly a multistep cascade-like process that requires a differential response to any given cytokine, but also integration of different signalling properties, e.g. changes in VEGF splice variant expression and interaction with angiopoietins. Only limited information about the role of other angiogenic or angiostatic factors in exercise is available, but metabolic regulators attracting attention include AMPK (AMP-activated protein kinase) and PGC-1α [PPAR (peroxisome-proliferator-activated receptor) γ coactivator 1α]. The participation of circulating endothelial progenitor cells, inflammatory cells and resident progenitor cells in skeletal muscle angiogenesis are developing areas of interest.
As understanding regulation of blood vessel growth and maturation is key to therapeutic angiogenesis, Andrea Banfi's group [3] examines the complexity of molecular and cellular interactions within the angiogenic microenvironment. The limitations of VEGF gene therapy in this context include chronic VEGF expression leading to aberrant vascular structures, development of vascular tumours (haemangiomas), and acute expression leading to unstable vessels. Indeed, in vivo VEGF gene delivery has a narrow therapeutic window: too low is ineffective, too high is unsafe. Understanding mechanisms of vascular maturation, including endothelial quiescence and resistance to VEGF withdrawal, involves interaction between a number of cell types (endothelium, smooth muscle cells, pericytes and myeloid accessory cells). Strategies to utilize vascular maturation as a therapeutic target involve co-expression of VEGF and Ang1 (angiopoietin 1), or VEGF and PDGF (platelet-derived growth factor)-BB, to avoid vascular leakage and increase collateral arteriogenesis respectively. The authors end with a plea for a systematic examination of efficacy and safety for specific combinations of factors in clinically relevant issues as a prerequisite for rational design of novel strategies for angiotherapy.
Signalling and angiogenesis
The second theme begins with genetic evidence pointing to an essential role for NRP1 (neuropilin-1) in cardiovascular development. NRP1 is thought to mediate its effects on the vasculature by binding VEGF that in turn binds to VEGFR (VEGF receptor) 2 to create VEGF-dependent NRP1-VEGFR2 holoreceptors, with greater biological activity than VEGFR2 dimer signalling alone. The article by Ian Zachary [4] focuses on the many unresolved questions that remain, including whether VEGF can signal via NRP1 independently of VEGFR2 and the extent of NRP1 and NRP2 interaction during VEGF signalling, and highlights recent findings that begin to answer them. Also discussed is the emerging area of NRP1 modulation of signalling by other tyrosine kinase receptors, such as hepatocyte growth factor/c-Met and PDGF, and the possible role of NRP1 cytosolic domain.
Angiopoietins act through the endothelial receptor tyrosine kinase Tie2, which in turn interacts with the related protein Tie1. Tie1 inhibits Ang1 signalling through Tie2, and the responsiveness of endothelium to Ang1 is determined by the relative levels of Tie2 and the inhibitory co-receptor Tie1 in the cell. Nicholas Brindle and colleagues [5] describe the tight control of Ang1 signalling. In particular how ectodomain cleavage of Tie1 by VEGF, inflammatory cytokines or changes in shear stress relieves inhibition of Tie2 by Tie1 and enhances Ang1 signalling. They conclude that regulation of signalling at the level of receptor responsiveness may be an important adaptation in systems in which activating ligand is normally present in excess, or where the ligand provides a constitutive maintenance signal.
Notch signalling is increasingly implicated in angiogenesis in normal tissues and tumours, and has recently become a major focus in the development of novel anticancer therapies. There is now much evidence that the VEGF and Delta/Notch pathways cross-talk, and that both are essential for angiogenesis. In particular, blockade of one pathway can produce compensatory changes in the other. Chern Oon and Adrian Harris [6] review the regulation of Dll4 (Delta-like ligand 4) expression, and possible mechanisms whereby Dll4 signalling can be extended via exosomes and bone marrow progenitor cells in the circulation. Its role in angiogenesis is described, and how it acts as a mechanism of resistance to antiangiogenic therapy. Important principles are established that may determine what is needed to develop effective therapy against Dll4.
HHT (hereditary haemorrhagic telangiectasia) is one of the few genetic vascular disorders that arise from mutations in endothelial genes, namely endoglin and ACVRL1 (activin receptor-like kinase 1). Both are expressed in ECs (endothelial cells) where they modulate TGFβ (transforming growth factor β) signalling. Endoglin acts as a TGFβ co-receptor and ACVRL1 is a TGFβ signalling receptor. Helen Arthur and group [7] discuss recent work describing the interaction of endoglin and ACVRL1 with other members of the TGFβ superfamily. Using conditional knockout mouse models, they describe how synergistic relationships with other signalling pathways has led to a better understanding of HHT disease, and the role of endoglin and ACVRL1 in maintaining normal cardiovascular health. A genome-wide association study suggests other roles will be discovered, e.g. a link is suggested between an endoglin haplotype and common cardiac malformations.
The PPARs belong to the nuclear receptor superfamily of ligand-activated transcription factors. The article by David Bishop-Bailey [8] focuses on the emerging roles of the PPARs in angiogenesis. Of the three human isoforms, PPARα and more strongly PPARγ are predominantly anti-angiogenic in vitro and in animal models. In contrast, PPARβ/δ is mainly a pro-angiogenic signalling molecule in tumour and physiological angiogenesis. An interesting facet of the PPARs in terms of angiogenesis is the availability of clinically used highly selective agonists such as rosiglitazone and fenofibrate that have been developed for other pathologies (e.g. diabetes and dislipidaemias respectively). It will be interesting to see whether low-molecular-mass agonists/antagonists of PPARs will have a role in the in vivo control of angiogenesis.
Mechanisms of vessel formation
Understanding how angiogenesis occurs in vivo under normal conditions, involving regulated expansion of the vasculature as a consequence of tight feedback control, is important in identifying the disrupted sequence of events and signalling pathways that occur in a range of diseases. Stuart Egginton [9] introduces the topic of physiological angiogenesis, suggesting that the local physical environment may play a prominent role in response to altered tissue demand. Utilizing a range of animal models, a variety of stromal and humoral signals evoked is seen to result in at least two different forms of capillary growth (splitting and sprouting angiogenesis). Although the endothelium is clearly an effective chemotransducer, especially under pathological conditions, regulation may be different during physiological responses, e.g. VEGF may be permissive, but not sufficient for angiogenesis. Mechanotransduction by ECs was explored by means of the response to elevated laminar shear stress, which is anti-atherogenic, but pro-angiogenic. Potential cellular components include the glycocalyx (disruption of a vasculoprotective layer), nitric oxide synthase [eNOS (endothelial nitric oxide synthase), but not nNOS (neuronal nitric oxide synthase), is crucial as part of vasodilatation] and CD31 (as part of a mechanosensory complex located intercellular junctions). All show differential responses to high-and low-shear-stress angiogenic stimuli in vivo.
Roy Bicknell's group [10] is particularly interested in genes whose expression is regulated by their environment. Comparison of SAGE (serial analysis of gene expression) libraries identified ∼ 600 genes that appear to be regulated by shear stress, a large proportion of which are involved in EC migration, adhesion and angiogenesis. Low shear stress is found at sites of vascular occlusion (e.g. thrombosis or embolism) and in the structurally poor vessels of solid tumours. Indeed, low shear induces expression of the endothelial-specific genes Robo4 (roundabout 4) and CLEC14A (C-type lectin 14A), possibly explaining why they are good markers for tumour endothelium. In a recurring theme, controversy over the role of Robo4 is resolved if its function is seen as context-dependent. Sprouting angiogenesis requires differentiation between quiescent ECs of the existing vessel (phalanx cells), those cells leading sprout migration through the extracellular matrix (tip cells) and ECs providing supporting connection between them (stalk cells). Reduced shear stress probably induces expression of a set of genes (including Robo4 and CLEC14A) to transform a stabilized phalanx cell into an active tip cell, thus stimulating angiogenesis in areas of poor perfusion. Both of these genes are associated with filopodia formation under conditions of low shear, whereas ECSCR (EC-specific chemotaxis regulator) also promotes filopodia formation and EC migration, but its expression is independent of shear stress. Markedly different signalling pathways underlying similar functions may therefore provide clues about regulation of complex cellular behaviour.
Although clinical trials of VEGF gene therapy have a good safety record, their efficacy has proved disappointing. This led Roberto Gianni-Barrera and colleagues [11] to develop a myoblast-based gene-delivery platform, using heterogeneous retroviral-transfected cells or isolated clonal populations, to deliver a range or similar amount of VEGF per cell. This showed that whether normal or aberrant angiogenesis is seen depends on the local, but not global, dose of VEGF. Using genetic manipulation of soluble isoforms (VEGF 120 ) and those with increasing affinity for extracellular matrix according to size (VEGF 164 , VEGF 188 ), in mouse hindbrain and retina demonstrate the importance of spatial distribution in differentiating between sprouting (tip cell migration) and enlargement (non-directional EC proliferation). Integration of the spatiotemporal cues provided by VEGF gradients involves signalling between Notch receptor and Dll transmembrane molecules, regulating the appropriate number of tip cells and hence control of vessel sprouting. Splitting angiogenesis may occur in the same tissue as sprouting angiogensis under different conditions or developmental stage, possibly involving alternative patterns of Notch activation.
Current therapeutic strategies to regulate angiogenesis are based around VEGF inhibition, either with monoclonal antibody sequestration or small kinase inhibition. Although this approach has generated positive results in some clinical trials, Andreas Bikfalvi's group [12] is examining how tumours react and adapt to anti-angiogenic therapies. Limitations include the need for associated chemotherapy, limited overall survival benefits, development of tumour resistance and the paradoxical enhancement of tumour progression following treatment. Resistance to anti-VEGF therapies can be evasive or intrinsic, involving a switch to alternative pathways [e.g. FGFs (fibroblast growth factors)], selection of hypoxia resistant cells or induction of gene expression leading to tumour cell invasiveness. Combination therapy is one way forward, with inhibition of VEGF and IL-6 (interleukin 6) pathways leading to greater efficacy than by individual inhibition. Anti-angiogenic, anti-invasive and antitumour properties of a C-terminal fragment of the chemokine CXCL4 (CXC chemokine ligand 4) (CXCL4CTF) or a homologue [CXCL4L1 (CXCL4-like 1)] represent a novel and potentially potent therapeutic and diagnostic option.
Novel regulators of endothelial biology and angiogenesis
Class 3 semaphorins are a family of secreted proteins originally identified as axon guidance factors that signal via binding to neuropilins and plexins. Carolyn Staton [13] reviews recent evidence that the class 3 semaphorins play a role in both physiological and pathological angiogenesis. Both the anti-angiogenic Sema3A and Sema3F are expressed by ECs, suggesting an autocrine function, whereas Sema3C is thought to be a pro-angiogenic factor. A loss of Sema3A expression in favour of VEGF may be responsible for the angiogenic switch in some cancers. Although our understanding of signalling is far from complete, there may be potential to therapeutically exploit Sema3A, Sema3F and Sema3B as anti-angiogenic and anti-tumour agents.
Another signalling protein that has recently attracted attention is RhoJ, an endothelial-specific member of the Cdc42 (cell division cycle 42) subfamily of small RhoGTPases, that regulates endothelial motility, tubulogenesis and lumen formation in vitro. Victoria Heath and colleagues [14] describes the in vivo vascular expression pattern and localization, and reviews the evidence from several groups, including her own, that RhoJ plays a key role in endothelial biology and in angiogenesis, as evidenced by its effect on vascularization of Matrigel TM plugs. Manipulation of RhoJ expression shows that it modulates the actin cytoskeleton and focal adhesions, crucial elements of endothelial migration during angiogenesis. However, in vivo, it is expressed in quiescent vessels. The identification of an endothelial-specific RhoGTPase will undoubtedly attract future interest and possibilities to unravel unknown functions.
The tetraspanins are a family of membrane proteins that function as organizers of the cell surface by recruiting specific partner proteins into tetraspanin-enriched microdomains. This organization allows the tetraspanins to regulate processes such as cell adhesion, signalling and intracellular trafficking. The group of Mike Tomlinson [15] show that 20 of the 33 known human tetraspanins are expressed in endothelium, and provide evidence that tetraspanins such as CD151 are required for endothelial tubulogenesis, possibly by facilitating endothelial cell-cell adhesion. CD151 is essential for pathological angiogenesis, perhaps involving the recruitment of leucocytes during inflammation. Mutations of other tetraspanins such as Tspan12 suggest a role in human disease. However, tetraspanins and angiogenesis remain an essentially unexplored area, and clearly many significant findings will follow.
The angiogenic properties of the chemokine RANTES (regulated upon activation, normal T-cell expressed and secreted)/CCL5 (CC chemokine ligand 5) signalling axis in the context of atherosclerosis are reviewed by Suffee et al. [16] , who outline the properties of chemokines and their potential role in angiogenesis, involving both in vitro and in vivo models, and the likely connection between their proangiogenic and pro-inflammatory roles. Whereas chemokines may promote endothelial migration and proliferation, and RANTES/CCL5 exerts a pro-angiogenic effect in a mouse model of ischaemia, this article highlights how the results currently remain controversial.
Angiogenesis and pre-eclampsia
Pre-eclampsia [or PET (pre-eclamptic toxaemia)] is a common condition, particularly among first pregnancies, and it remains a leading cause of maternal morbidity and mortality, as well as fetal complications due to growth restrictions or premature delivery. It presents with a range of clinical vascular manifestations including hypertension, seizures, cerebral and pulmonary oedema, renal failure and proteinuria. The only effective treatment is delivery of the fetus/removal of the placenta. It is thought to be mediated by circulating factors, as plasma from pre-eclamptic women has biological activity on endothelium not found with plasma from normal pregnancies. The factors involved have been narrowed down to members of the VEGF family of proteins and their receptors, and activity of VEGF-A probably regulated by sequestration by either PlGF (placental growth factor) or the ectodomain of a receptor, sVEGFR1 (soluble VEGFR1). Several years ago, the Bates group described alternatively spliced forms of VEGF, called the VEGFb isoforms, and showed that these can be inhibitory to the previously identified 'a' forms. In his article, Dave Bates [17] discusses the role of VEGF and VEGFR expression in PET, suggests that altered bioavailability of VEGF isoforms may be responsible, and argues that VEGF 165 b may be one family member that is implicated in this toxicity. Excessive inflammation, possibly in response to foreign bodies (i.e. sperm), has been proposed as an alternative to the imbalance in angiogenic factors as a cause of PET. The second article in this section, by Asif Ahmed and Wenda Ramma [18] , argues that pre-eclampsia is a pathology driven by excessive angiogenesis, rather than by inflammation. This is based in part on the lack of response to corticosteroids and of a doseresponse relationship between inflammatory cytokines and pre-eclampsia. In contrast, the increase in sVEGFR1 and soluble endoglin, and decrease in PlGF fulfils the criterion of causality.
Methods
Key to the future of any field is development of new methods. Recognizing that "recreating angiogenesis in vitro is probably an impossible goal", Harry Mellor's group [19] contrasted the Matrigel TM assay, where ECs are plated on basement membrane and extracellular matrix components extracted from tumour cells, with the organotypic co-culture assay, where ECs are grown in the presence of fibroblasts that secrete extracellular matrix and growth factors. In the latter, the matrix is actively remodelled, giving a composition similar to that found in wound healing. An optimized protocol allows a realistic timeframe for transfection with siRNA (small interfering RNA) oligonucleotides and the potential screening for regulators of angiogenesis. Selection of EC phenotype by FACS is assisted by shRNA (small hairpin RNA) transfection, and tube formation visualized by immunohistochemistry to permit quantitative analysis. Although limitations remain, e.g. difficulty in establishing growth factor gradients, it is a powerful tool that allows precise roles of proteins in the different cellular processes during angiogenesis to be elucidated.
Friedemann Kiefer's group [20] studies the second vascular system of vertebrates (the lymphatics) that plays an important role in tissue fluid homoeostasis, dietary fat resorption, and immune surveillance. LECs (lymphatic ECs) are characterized by expression of unique genes distinguishing them from BECs (blood vessel ECs). The first marker of lymphatic differentiation is the hyaluron receptor Lyve-1, with VEGFR3 becoming restricted to LECs during development and its ligand VEGF-C promoting migration, sprouting, proliferation and survival. A crucial step in lymphatic development is separation from the blood circulation, with important roles for platelets and myeloid cells. Maturation of LECs involves the transmembrane Ephreceptor ligand ephrinB2, and remodelling the transcription factor FoxC2 (forkhead box C2). As with angiogenesis, regulation of sprouting from an existing vasculature, subsequent pruning and maturation, and interactions with different cell and tissue types is a complex process. A powerful development in imaging technology, two-photon laser-scanning intravital microscopy, allows deep tissue imaging. Colourcoded lymphatic vessels using the homeobox transcription factor Prox1 (Prospero homeobox protein 1) (the 'master regulator' of lymphatic phenotype) promoter to drive in vivo expression of mOrange2 protein in LECs produces superb quality pictures, allowing visualization of embryological lymphatic development for the first time.
It is usually assumed that once committed to a particular lineage during embryological development, BECs or LECs are committed to their fate. Poster prize winner Lindsay Cooley [21] suggests that various degrees of plasticity are retained, and that exploiting the ability to express characteristics of alternative cell lineages may provide insight into the genesis of several vascular diseases. Repulsive ephrinB2/EphB2 signalling leads to arteriovenous separation, with Notch signalling the key regulator of arterial fate, and COUP-TFII (chicken ovalbumin upstream promotertranscription factor 2) repression of Notch a positive regulator of venous fate. However, grafted vessels are able to develop characteristics of host vessels in response to environmental cues such as blood flow and cellcell interactions. Recent evidence suggests that venouslymphatic lineage specification is also more plastic than previously believed. Although reprogramming BEC-to LEC-linkage can be directed by ectopic expression of Prox1, this study shows the first example of spontaneous change in expression of lineage-specific genes by an altered extracellular environment. Possible mechanisms include the role of inflammatory cytokines, intercellular interactions, cell-extracellular matrix interaction and balance of lineage regulator genes. Recognition that endothelial phenotype may be regulated by environmental as well as genetic cues raises therapeutic possibilities, such as amelioration of lymphoedema or inhibition of tumour lymphangiogenesis.
